INDP

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Wall Street analysts forecast INDP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDP is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Indaptus Therapeutics Inc revenue for the last quarter amounts to -2.65M USD, decreased -15.71 % YoY.

Indaptus Therapeutics Inc. EPS for the last quarter amounts to USD, decreased % YoY.

Indaptus Therapeutics Inc (INDP) has 7 emplpoyees as of January 10 2026.

Today INDP has the market capitalization of 5.48M USD.